Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical

Exact Sciences develops innovative diagnostics tests that help intercept cancer early. Intuitive Surgical's famous robotic surgical system has important benefits for patients.

2 Revolutionary Stocks to Buy and Hold for 10 Years

Exact Sciences, specializing in advanced cancer diagnostics, is recognized for its cutting-edge tests facilitating early cancer detection. 2022 saw significant milestones, testing over 12 million individuals and broadening its global healthcare network to over 350,000 providers. Moving forward, the company is prioritizing colon cancer screening, precision oncology, and molecular residual disease detection as key growth strategies.

Exact Sciences: Revolutionizing Cancer Detection With Innovation

Twist Bioscience Corp

Cathie Wood's Ark Innovation ETF has been blazing the comeback trail in 2023. Among the fund's various holdings, Twist Biosciences and Exact Sciences stand out as top growth plays right now.

2 Cathie Wood Growth Stocks That Could Make You Richer

Celsius Holdings

Copart

DraftKings

Marriott

We have narrowed our search to five Nasdaq Composite listed non-technology stocks. These are: CELH, DKNG, CPRT, EXAS, MAR.

Top 5 Non-Tech Nasdaq Winners of 1H With More Upside Left

MADISON, Wis., July 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after the close of the U.S. financial markets on August 1, 2023.

Exact Sciences schedules second quarter 2023 earnings call

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard growth and raised guidance.

Here's Why You Should Buy Exact Sciences (EXAS) Stock Now

Analysts project Exact Sciences' stock will fall from here. The company has generated strong revenue growth.

Analysts Think This Soaring Cathie Wood Stock Has Peaked. Are They Right?

Shopify

Block

Tesla

Much has been written and discussed about the incredible success and then failure of Cathie Woods and the phenomenal ARK Innovation exchange-traded fund, which exploded in 2020, only to implode in the fall of 2021 and trade sideways for most of 2022.

5 Cathie Woods ARK Innovation Top Holdings Are Huge Buy and Hold Forever Winners

Does Exact Sciences (EXAS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Exact Sciences (EXAS) is a Great Choice

Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancing 35.11% in the past three months and 81.34% year-to-date.

Analysts Bullish On Exact Sciences' Advanced Cancer Screening

Pinterest

Exact Sciences' laudable goal of fighting cancer turns out to be good for investors, too. Pinterest can make headway by integrating e-commerce capabilities into its platform.

2 Stocks to Invest $500 In and Hold For 10 Years

Exact Sciences' next-generation Cologuard test shows improved specificity, cancer sensitivity, and precancer sensitivity, which could lead to better insurance coverage and increased reimbursements. The successful BLUE-C study and potential FDA approval for the upgraded test may drive revenues higher than previously forecasted. Despite the promising results, the company's current valuation holds significant risks.

Exact Sciences: The Future Of Colorectal Cancer Screening And The Impact Of BLUE-C Study Results

Here is how Exact Sciences (EXAS) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

Is Exact Sciences (EXAS) Outperforming Other Medical Stocks This Year?

Shares of Exact Sciences Corp. EXAS, +0.98% gained more than 7% in premarket trading Wednesday after the company released results from a study of its next-generation Cologuard, a non-invasive colorectal cancer screening test. In a study with 20,000 participants age 40 and older, the updated version of the test correctly detected cancer in 94% of cases and correctly produced negative results 91% of the time, the company said in a release.

Exact Sciences shares gain on results from non-invasive cancer screening test

Exact Sciences (NASDAQ:EXAS) shares rose in Wednesday pre-market trading after the molecular diagnostics company specializing in the detection of early-stage cancers announced positive top-line results from its pivotal BLUE-C study.  The company said the results show that its next-generation Cologuard test demonstrated 94% sensitivity for colorectal cancer at 91% specificity, raising the bar in non-invasive screening.

Exact Sciences set to rally on positive top-line results from pivotal BLUE-C study

Agreements with Broad Institute of MIT and Harvard provide exclusive license to next-generation technology for ultra-sensitive detection of molecular residual disease and ongoing research Collaboration with Baylor Scott & White creates real-world experience and evidence supporting Exact Sciences' multi-cancer early detection approach MADISON, Wis. , June 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced separate collaborations with two renowned healthcare organizations at the forefront of cancer research.

Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations

Exact Sciences said Tuesday the company's next-generation Cologuard outperformed the original test. The results stoked EXAS stock.

Why Exact Sciences Stock With 222% Growth Just Surged Again

Exact Sciences said on Tuesday its next-generation screening test for colon cancer showed 30% lower false positive rate for detecting the disease in a study when compared to trial data on its already approved test.

Exact Sciences says its new colon cancer test shows 30% lower false positive rate

BLUE-C study met all endpoints, showing improved cancer sensitivity, specificity, and precancer sensitivity 20,000-participant study reflects racial and ethnic diversity of the U.S. Company plans to complete FDA submission for next-generation Cologuard by end of 2023 MADISON, Wis. , June 20, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced positive top-line results from the pivotal BLUE-C study.

Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening

Aurora Innovation

Schrodinger 

Finding early-stage, revolutionary companies whose market capitalizations can reach $1 trillion can be very lucrative. Just look atAlphabet (NASDAQ:  GOOG, NASDAQ: GOOGL ), Apple (NASDAQ: AAPL ), and Amazon (NASDAQ: AMZN ).

3 Revolutionary Companies With Trillion-Dollar Potential

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Why Is Exact Sciences (EXAS) Up 11.5% Since Last Earnings Report?

Award marks fifth consecutive year company has received prestigious distinction MADISON, Wis. , June 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2023 Great Place To Work® for the fifth consecutive year.

EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK® CERTIFICATION™

MADISON, Wis. , June 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

Exact Sciences to participate in June investor conferences

Exact Sciences' approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial1-2 Surveillance, Epidemiology, and End Results (SEER) program analysis shows continued, long- term confidence in prognostic value of the Oncotype DX Breast Recurrence Score® 3 New modeling data show superior health outcomes in colorectal cancer screening with Cologuard® compared to blood-based tests, including lower mortality and more life-years gained4,5 MADISON, Wis. , May 26, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it will present 15 abstracts at the American Society of Clinical Oncology® (ASCO®) Annual Meeting 2023, June 2-6, in Chicago, Illinois.

Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023

Tesla, DraftKings, and Exact Sciences all saw their shares tank in 2022. But this year they have been some of the ARK Innovation ETF's best performers.

News for Exact Sciences Stock (EXAS)